Valuation: Physiomics Plc

Market Cap 2.15M 2.88M 2.52M 2.32M 4.09M 274M 4.14M 27.76M 10.8M 135M 10.8M 10.56M 467M P/E 2026 *
-4.75x
P/E 2027 * -
Enterprise Value 1.89M 2.52M 2.21M 2.03M 3.58M 240M 3.63M 24.33M 9.47M 118M 9.46M 9.26M 409M EV / Sales 2026 *
1.89x
EV / Sales 2027 * -
Free-Float
75.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

1 month-20.83%
3 months+4.40%
6 months+66.67%
Current year+66.67%
1 week 0.47
Extreme 0.4725
0.5
1 month 0.4
Extreme 0.4
0.64
Current year 0.25
Extreme 0.2525
0.8
1 year 0.25
Extreme 0.2525
0.8
3 years 0.25
Extreme 0.2525
3.19
5 years 0.25
Extreme 0.2525
7.28
10 years 0.25
Extreme 0.2525
32
Manager TitleAgeSince
Director of Finance/CFO 52 -
Corporate Officer/Principal - 2021-08-30
Chief Administrative Officer - 2007-12-31
Director TitleAgeSince
Director/Board Member - 2026-04-28
Chairman 53 2026-04-28
Director/Board Member - 2026-04-28
Date Insider Type Main position Quantity % Market Cap.
24-11-07Buy

Chief Executive Officer

459,090 0.2259%
24-02-05Free

Chief Executive Officer

1,354,725 1.0000%
24-02-05Free

Chief Executive Officer

1,354,725 1.0000%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+14.46%-51.28% 2.88M
-0.96%+8.99%-16.28%+12.87% 132B
+0.46%+10.54%+5.29%+31.23% 44.7B
+5.68%+13.85%-52.76%-24.67% 38.3B
+3.00%+11.70%-32.87%-21.42% 20.47B
-0.38%+6.22%-1.51%+66.85% 15.76B
+1.23%+11.13%-12.38%+4.82% 15.29B
+3.97%+6.63%-56.86%-45.09% 14.8B
+1.54%+11.59%-42.68%-33.76% 8.97B
-2.89%-4.87%+100.13%+51.28% 5.29B
Average +1.16%+4.80%-9.55%-0.91% 29.59B
Weighted average by Cap. +0.82%+8.87%-18.65%+7.25%

Financials

2026 *2027 *
Net sales 1M 1.34M 1.17M 1.08M 1.9M 127M 1.92M 12.9M 5.02M 62.53M 5.02M 4.91M 217M -
Net income -314K -419K -367K -338K -596K -40M -604K -4.05M -1.58M -19.64M -1.57M -1.54M -68.08M -
Net Debt -266K -355K -311K -287K -505K -33.89M -512K -3.43M -1.34M -16.63M -1.33M -1.3M -57.67M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
10
Date Price Change Volume
26-07-07 GBX 0.4750 0.00% 273,617
26-07-06 GBX 0.4750 0.00% 33,205
26-07-03 GBX 0.4750 0.00% 243,237
26-07-02 GBX 0.4750 0.00% 2,050,325
26-07-01 GBX 0.4750 0.00% 1,317,300

Annual profits - Rate of surprise